முழுமை பதில் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jul 07 2021 STELFONTA® (tigilanol tiglate) is now approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT). APVMA approval follows marketing authorisation (registration) and launch of STELFONTA® in the major companion animal markets of the US, Europe, and the United Kingdom. STELFONTA® will be available to Australian veterinarians, including oncologists and general practitioners, in October 2021 through QBiotics’ marketing and distribution partner, Virbac – a global animal health company. BRISBANE, Australia, July 7, 2021 /PRNewswire/ – QBiotics Group Limited (QBiotics), an Australian life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce the Australian Pesticides and Veterinary Medicines Authority (APVMA) has approved its lead veterinary product STELFONTA® (tigilanol tiglate). This approval represents Austral

United kingdomQbiotics group limitedEuropean medicines agencyDrug administrationVeterinary medicines authorityAustralian pesticidesGroup limitedManaging directorComplete responseVeterinary medicines directorateஒன்றுபட்டது கிஂக்டம்கால்நடை மருந்துகள் அதிகாரம்ஆஸ்திரேலிய பூச்சிக்கொல்லிகள்குழு வரையறுக்கப்பட்டவைநிர்வகித்தல் இயக்குனர்முழுமை பதில்